Anlotinib improves bile duct ligature‐induced liver fibrosis in rats via antiangiogenesis regulated by VEGFR2/mTOR pathway
Sign Up to like & getrecommendations! Published in 2022 at "Drug Development Research"
DOI: 10.1002/ddr.22019
Abstract: Cholestasis is a main clinical feature of biliary atresia (BA), which leads to liver fibrosis (LF). The focus of BA treatment is preventing and slowing the progress of LF. This study reports the improvement effect… read more here.
Keywords: anlotinib; expression; effect anlotinib; phospho ... See more keywords
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-020-02641-5
Abstract: Background Many anti-angiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy. Anlotinib has demonstrated anti-tumor efficacy in non-small cell lung cancer (NSCLC) in third-line clinical trials. However, its roles in immune… read more here.
Keywords: anti tumor; anlotinib; lung cancer; tumor ... See more keywords
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Immunology, Immunotherapy"
DOI: 10.1007/s00262-021-02869-9
Abstract: This study evaluated the efficacy and safety of anlotinib combined with programmed cell death protein 1 (PD-1) blockade for the treatment of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). SCLC (n = 28) and NSCLC… read more here.
Keywords: inhibitor; treatment; anlotinib; lung cancer ... See more keywords
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2018 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.05.013
Abstract: OBJECTIVES Anlotinib is a novel multi-target tyrosine Kinase inhibitor that inhibits VEGFR2/3, FGFR1-4, PDGFD α/β, c-Kit and Ret. In the phase III ALTER-0303 trial (Clinical Trial Registry ID: NCT 02388919), anlotinib significantly improved overall survival… read more here.
Keywords: placebo; quality life; anlotinib; lung cancer ... See more keywords
Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells
Sign Up to like & getrecommendations! Published in 2020 at "Acta Pharmacologica Sinica"
DOI: 10.1038/s41401-020-0421-7
Abstract: Anlotinib, a multitarget tyrosine kinase inhibitor, is effective as a third-line treatment against non-small cell lung cancer (NSCLC). However, acquired resistance occurs during its administration. To understand the molecular mechanisms of anlotinib resistance, we characterized… read more here.
Keywords: accessibility; anlotinib; resistance; lung cancer ... See more keywords
Combination of eribulin and anlotinib exerts synergistic cytotoxicity in retroperitoneal liposarcoma by inducing endoplasmic reticulum stress
Sign Up to like & getrecommendations! Published in 2024 at "Cell Death Discovery"
DOI: 10.1038/s41420-024-02103-2
Abstract: Primary retroperitoneal liposarcoma (RLPS) is a rare heterogeneous tumor occurring within retroperitoneal space, and its overall survival has not improved much in the past few decades. Based on a small-sample clinical practice at our center,… read more here.
Keywords: reticulum stress; combination; endoplasmic reticulum; anlotinib ... See more keywords
RADT-27. EFFICACY AND SAFETY OF ANLOTINIB COMBINED WITH CRANIAL RADIOTHERAPY IN NON-SMALL CELL LUNG CARCINOMA PATIENTS WITH BRAIN METASTASES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0397
Abstract: Brain metastases (BM) from non-small cell lung cancer (NSCLC) pose significant treatment challenges, with limited intracranial control despite cranial radiotherapy (CRT). Anlotinib, a multi-targeted tyrosine kinase inhibitor, has shown potential synergy with CRT. This meta-analysis… read more here.
Keywords: brain metastases; meta; analysis; anlotinib ... See more keywords
Salvage anlotinib showed sustained efficacy in heavily pretreated EGFR wild-type lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Medicine"
DOI: 10.1097/md.0000000000022707
Abstract: Abstract Rationale: Anlotinib has been proved to be effective in advanced refractory non-small cell lung cancer. Patient concerns: A 47-year-old female non-smoker was admitted due to persistent chest tightness for a month. Diagnoses: Epidermal growth… read more here.
Keywords: anlotinib; lung; lung adenocarcinoma; egfr wild ... See more keywords
Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-2950
Abstract: Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a novel multitarget tyrosine kinase inhibitor targeting VEGFR, PDGFR,… read more here.
Keywords: anlotinib; phase iib; randomized double; medullary thyroid ... See more keywords
Abstract 5964: Real world efficacy and safety of anlotinib in solid tumors previously treated with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5964
Abstract: Backgrouds Immune checkpoint inhibitors (ICIs) resistance of solid tumors is common and subsequent treatment options offer limited clinical benefit. Anlotinib is a novel multitarget tyrosine kinase inhibitor (TKI) for tumor angiogenesis and proliferative signaling. Recent… read more here.
Keywords: cancer; solid tumors; real world; tumors previously ... See more keywords
Abstract CT170: ALTAS: A phase II trial of anlotinib in combination with TAS-102 in patients with metastatic colorectal cancers
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-ct170
Abstract: The management of metastatic colorectal cancer (mCRC) in late-line settings remains a formidable challenge, as existing therapies yield limited clinical benefits. The SUNLIGHT trial, which evaluated TAS-102 in combination with bevacizumab, reported a median progression-free… read more here.
Keywords: combination; metastatic colorectal; trial; altas phase ... See more keywords